Ono Pharmaceutical (OTCMKTS:OPHLY – Get Free Report) is expected to be posting its resultson Friday, July 31st. Analysts expect the company to post earnings of $0.0716 per share and revenue of $685.0340 million for the quarter.
Ono Pharmaceutical Trading Down 0.7%
Shares of OTCMKTS OPHLY opened at $4.82 on Friday. The firm’s 50-day moving average price is $4.84 and its 200-day moving average price is $5.00. Ono Pharmaceutical has a 1-year low of $3.55 and a 1-year high of $5.75.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
